发明授权
EP1694659B1 THIADIAZOLES AS CXC- AND CC- CHEMOKINE RECEPTOR LIGANDS
有权
THIADIAZOLES作为CXC-和CC-趋化因子受体配体
- 专利标题： THIADIAZOLES AS CXC- AND CC- CHEMOKINE RECEPTOR LIGANDS
- 专利标题（中）： THIADIAZOLES作为CXC-和CC-趋化因子受体配体
-
申请号： EP04814266.5申请日： 2004-12-16
-
公开(公告)号： EP1694659B1公开(公告)日： 2008-08-27
- 发明人: BIJU, Purakkattle, J. , TAVERAS, Arthur, G. , YU, Younong , ZHENG, Junying , CHAO, Jianhua , AKI, Cynthia, J. , FINE, Jay , LUNDELL, Daniel , PRIESTLEY, Tony , REGGIANI, Angelo , MERRITT, J., Robert , BALDWIN, John, J.
- 申请人： Schering Corporation , Pharmacopeia Drug Discovery, Inc.
- 申请人地址： 2000 Galloping Hill Road Kenilworth, New Jersey 07033 US
- 专利权人： Schering Corporation,Pharmacopeia Drug Discovery, Inc.
- 当前专利权人： Schering Corporation,Pharmacopeia Drug Discovery, Inc.
- 当前专利权人地址： 2000 Galloping Hill Road Kenilworth, New Jersey 07033 US
- 代理机构： UEXKÜLL & STOLBERG
- 优先权： US531311P 20031219; US531713P 20031222
- 国际公布： WO2005066147 20050721
- 主分类号： C07D285/10
- IPC分类号： C07D285/10 ; C07D417/12 ; C07D417/14 ; A61K31/433 ; A61K31/4436
摘要：
Disclosed are novel compounds of Formula (IA) and the pharmaceutically acceptable salts and solvates thereof. Examples of groups comprising Substituent A include heteroaryl, aryl, heterocycloalkyl, cycloalkyl, aryl, alkynyl, alkenyl, aminoalkyl, alkyl or amino. Examples of groups comprising Substituent B include aryl and heteroaryl. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer, angiogenisis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke and ischemia reperfusion injury, pain (e.g., acute pain, acute and chronic inflammatory pain, and neuropathic pain) using a compound of Formula (IA).
公开/授权文献
- EP1694659B8 THIADIAZOLES AS CXC- AND CC- CHEMOKINE RECEPTOR LIGANDS 公开/授权日：2008-10-08
信息查询
